Abstract:Simple Summary Breast cancer (BC) is a serious threat to women's health and metastasis is the major cause of BC-associated mortality. Failure to detect and remove occult micrometastases limits the control of tumor recurrences. More precise non-invasive strategy needs to be developed for the detection of the tumor metastasis in lymph nodes and distant organs. Here, we suppose that the metabolomic method can be used to achieve non-invasive and real-time monitoring of BC metastatic status. We firstly described the metastatic status of BC mouse models with different tumor-bearing times. Secondly, metabonomics analysis and metastasis-related changes in the tumor microenvironment (TME) were performed in tumor-bearing mice with different metastatic states. The results showed that TME evolution can establish a link between metabolomics characteristics and tumor metastatic status. Finally, the changes of differential metabolite levels were also preliminarily confirmed in clinical BC samples and found that metabolite lysoPC (16:0) can be used for clinical N-stage diagnosis, and the possible causes of its changes was analyzed through bioinformatics technology. Breast cancer (BC) is a serious threat to women's health and metastasis is the major cause of BC-associated mortality. Various techniques are currently used to preoperatively describe the metastatic status of tumors, based on which a comprehensive treatment protocol was determined. However, accurately staging a tumor before surgery remains a challenge, which may lead to the miss of optimal treatment options. More severely, the failure to detect and remove occult micrometastases often causes tumor recurrences. There is an urgent need to develop a more precise and non-invasive strategy for the detection of the tumor metastasis in lymph nodes and distant organs. Based on the facts that tumor metastasis is closely related to the primary tumor microenvironment (TME) evolutions and that metabolomics profiling of the circulatory system can precisely reflect subtle changes within TME, we suppose whether metabolomic technology can be used to achieve non-invasive and real-time monitoring of BC metastatic status. In this study, the metastasis status of BC mouse models with different tumor-bearing times was firstly depicted to mimic clinical anatomic TNM staging system. Metabolomic profiling together with metastasis-related changes in TME among tumor-bearing mice with different metastatic status was conducted. A range of differential metabolites reflecting tumor metastatic states were screened and in vivo experiments proved that two main metastasis-driving factors in TME, TGF-beta and hypoxia, were closely related to the regular changes of these metabolites. The differential metabolites level changes were also preliminarily confirmed in a limited number of clinical BC samples. Metabolite lysoPC (16:0) was found to be useful for clinical N stage diagnosis and the possible cause of its changes was analyzed by bioinformatics techniques.

Metabolomic Detection Between Pancreatic Cancer and Liver Metastasis Nude Mouse Models Constructed by Using the PANC1-KAI1/CD<sub>82</sub> Cell Line

Integrative metabolomic characterisation identifies altered portal vein serum metabolome contributing to human hepatocellular carcinoma

High-Fat Mouse Model to Explore the Relationship between Abnormal Lipid Metabolism and Enolase in Pancreatic Cancer

Tissue metabolomics identified new biomarkers for the diagnosis and prognosis prediction of pancreatic cancer

Construction and Validation of Risk Factors and Prognostic Model for Liver Metastasis of Pancreatic Cancer

Metabonomic alterations from pancreatic intraepithelial neoplasia to pancreatic ductal adenocarcinoma facilitate the identification of biomarkers in serum for early diagnosis of pancreatic cancer

Gas Chromatography/Time-Of-Flight Mass Spectrometry-Based Metabonomics of Hepatocarcinoma in Rats with Lung Metastasis: Elucidation of the Metabolic Characteristics of Hepatocarcinoma at Formation and Metastasis

Experimental animal models of pancreatic carcinogenesis and liver metastasis and me-tastasis-related molecules

1H-Nmr-based Metabolic Profiling of a Colorectal Cancer CT-26 Lung Metastasis Model in Mice.

1H-NMR-based metabolomics of tumor tissue for the metabolic characterization of rat hepatocellular carcinoma formation and metastasis

Non-Invasive and Real-Time Monitoring of the Breast Cancer Metastasis Degree via Metabolomics

Metabolomics identifies serum and exosomes metabolite markers of pancreatic cancer

Metabolomics Identifies Biomarker Signatures to Differentiate Pancreatic Cancer from Type 2 Diabetes Mellitus in Early Diagnosis

Metabolomic Profiling of Serum from Human Pancreatic Cancer Patients Using 1H NMR Spectroscopy and Principal Component Analysis

Identification of Liver Metastasis-Related Genes in A Novel Human Pancreatic Carcinoma Cell Model by Microarray Analysis

Untargeted metabolomics characterization of the resectable pancreatic ductal adenocarcinoma

Metabolomic analysis of circulating tumor cells derived liver metastasis of colorectal cancer

Revealing Different Lung Metastatic Potentials Induced Metabolic Alterations of Hepatocellular Carcinoma Cells Via Proton Nuclear Magnetic Resonance Spectroscopy

Establishment of Three Human Pancreatic Cancer Orthotopic Xenograft Nude Mice Models and Serum Metabolomics

Proteomic Study on Multi-Organ Metastases of Human Ovarian Clear Cell Carcinoma Cell Line in a Xenograft Mouse Model Based on a Novel Sequence-Specific Analysis Strategy

A Metabolism-Relevant Signature As a Predictor for Prognosis and Therapeutic Response in Pancreatic Cancer.